Table 2.
Characteristics of patients with IBD undergoing colonoscopy.
| Crohn’s disease (n = 20) | Ulcerative colitis (n = 15) | |||
|---|---|---|---|---|
| Montreal classification, n (%) | Age at diagnosis, years | Disease extent | ||
| <17 | 2 (10) | Proctitis | 0 (0) | |
| 17–40 | 15 (75) | Left-sided colitis | 9 (60) | |
| >40 | 3 (15) | Extensive colitis | 6 (40) | |
| Location | Disease severity | |||
| Ileal | 2 (10) | Clinical remission | 6 (40) | |
| Colonic | 9 (45) | Mild | 4 (27) | |
| Ileocolonic | 9 (45) | Moderate | 5 (33) | |
| Upper gastrointestinal | 0 (0) | Severe | 0 (0) | |
| Behaviour | ||||
| Nonstricturing, nonpenetrating | 9 (45) | |||
| Stricturing | 3 (15) | |||
| Penetrating/fistulizing | 8 (40) | |||
| Perianal | 8 (40) | |||
| Clinical disease activity |
Harvey Bradshaw index
median (range) |
5 (0–18) |
Simple clinical colitis activity index
median (range) |
3 (0–8) |
| Medical therapy, n (%) | Nil | 1 (5) | 1 (7) | |
| 5-ASA only | 2 (10) | 6 (40) | ||
| Steroids ± 5-ASA | 0 (0) | 1 (7) | ||
| Azathioprine/6-MP ± 5-ASA / steroids | 7 (35) | 6 (40) | ||
| Methotrexate ± 5-ASA/ steroids | 2 (10) | 1 (7) | ||
| Infliximab/adalimumab ± 5-ASA/steroids | 1 (5) | 0 (0) | ||
| Infliximab/adalimumab ± immunomodulators | 7 (35) | 0 (0) | ||
| Previous intestinal surgery, n (%) | Single ileocolonic resection | 5 (25) | ||
| Multiple ileocolonic resections | 2 (10) | |||
5-ASA, 5-aminosalicylates; 6-MP, 6-mercaptopurine; IBD, inflammatory bowel disease.